Multiple Myeloma

Disease Overview

What Is Myeloma?

Effective risk stratification remains one of the key challenges in multiple myeloma management. PlasmaSEQ addresses this challenge through comprehensive genomic profiling, delivering clinically relevant insights from as little as 1 ng/µL of DNA and maximizing the value of limited biological samples.

As a DNA-based assay, PlasmaSEQ is less susceptible to pre-analytical variables associated with sample transport and handling, helping ensure consistent performance across diverse clinical settings.

With targeted sequencing coverage exceeding 500×, PlasmaSEQ can detect mutations present in clones as low as 1.3%*

Clinical Adoption

What Clinicians Are Saying

Trusted by clinicians, researchers, and healthcare professionals.

“PlasmaSEQ has significantly improved our ability to identify critical genomic events with remarkable accuracy. The turnaround time has been excellent.”

“The quality of reporting and bioinformatics support provided by NCGM has been exceptional. Their team consistently delivers reliable results.”

“The comprehensive genomic profiling offered by PlasmaSEQ has simplified our diagnostic workflow and reduced dependency on multiple assays.”

“We appreciate the accuracy, speed, and scientific expertise demonstrated by the NCGM team. Their services have become an important part of our clinical practice.”

“PlasmaSEQ has significantly improved our ability to identify critical genomic events with remarkable accuracy. The turnaround time has been excellent.”

“The quality of reporting and bioinformatics support provided by NCGM has been exceptional. Their team consistently delivers reliable results.”

“The comprehensive genomic profiling offered by PlasmaSEQ has simplified our diagnostic workflow and reduced dependency on multiple assays.”

“We appreciate the accuracy, speed, and scientific expertise demonstrated by the NCGM team. Their services have become an important part of our clinical practice.”